DENVER, May 14, 2024 /PRNewswire/ -- Today, DaVita (NYSE: DVA) published its 2023 Community Care Report, underscoring its dedication to corporate social responsibility and commitment to setting a new standard for health care services. DaVita's annual Community Care Report examines progress toward its 2025 Environmental, Social, and Governance (ESG) goals to help improve the lives of patients and support the health of communities globally.
The report highlights 2023 milestones across five strategic focus areas:
"The sustained progress outlined in this report underscores our vision for an unwavering pursuit of a healthier tomorrow," said Javier Rodriguez, chief executive officer for DaVita. "Building a healthier tomorrow begins with excellence in patient care and extends to our positive impact on the communities we serve. I'm proud to work alongside dedicated teammates who are deeply committed to uplifting our patients, each other and our world."
Following are 2023 standout achievements from each of the five focus areas reflected in the report.
Patient Care
Teammate Engagement
Environmental Stewardship
Healthy Communities
Leading with Integrity & Accountability
To learn more about DaVita's vision for corporate citizenship or to download the full report, visit DaVita.com/CommunityCare.
Forward Looking Statements:
This press release contains or refers to certain forward-looking statements within the meaning of the federal securities laws including, among other things. Without limiting the foregoing, statements including the words "expect," "intend," "will," "may," "continue," "target," "goal" and similar expressions are intended to identify forward-looking statements. The Company bases its forward-looking statements on information available to it on the date of this press release, and undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of changed circumstances, new information, future events or otherwise, except as may otherwise be required by law. Actual future events could also differ materially due to numerous factors that involve substantial known and unknown risks and uncertainties including, among other things, the risks and uncertainties set forth under "Risk Factors" and elsewhere in the Company's reports on Form 10-K and Form 10-Q and the other risks and uncertainties discussed in any subsequent reports that the Company files with the Securities and Exchange Commission from time to time.
About DaVita Inc.
DaVita (NYSE: DVA) is a health care provider focused on transforming care delivery to improve quality of life for patients globally. The company is one of the largest providers of kidney care services in the U.S. and has been a leader in clinical quality and innovation for more than 20 years. DaVita cares for patients at every stage and setting along their kidney health journey—from slowing the progression of kidney disease to helping to support transplantation, from acute hospital care to dialysis at home. As of March 31, 2024, DaVita served approximately 258,600 patients at 3,092 outpatient dialysis centers, of which 2,665 centers were located in the United States and 427 centers were located in 12 other countries worldwide. DaVita has reduced hospitalizations, improved mortality, and worked collaboratively to propel the kidney care industry to adopt an equitable and high-quality standard of care for all patients, everywhere. To learn more, visit DaVita.com/About.
CONTACTS:
DaVita Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$160.33 |
Daily Change: | 5.97 3.87 |
Daily Volume: | 1,150,153 |
Market Cap: | US$13.450B |
October 29, 2024 October 23, 2024 October 17, 2024 September 13, 2024 August 06, 2024 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB